12:00 AM
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

IDegLira regulatory update

Novo Nordisk disclosed in its 1H13 earnings that it submitted a regulatory application in Switzerland for IDegLira to treat Type II diabetes. IDegLira, which is under review in the EU, is a...

Read the full 138 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >